Bicara Therapeutics is progressing its Phase 3 trial of ficerafusp alfa for head and neck cancer, expecting interim results by mid-2027 that could support accelerated approval. The company holds nearly $500 million in cash and securities, funding operations into early 2029. Despite a Q2 net loss of $55.4 million, analysts remain optimistic, raising price targets to $35 and $39. This financial strength and clinical progress position Bicara as a promising player in cancer therapy development.
ExxonMobil maintains a buy rating due to strong free cash flow, disciplined capital spending, and attractive valuation. In Q2, the company achieved record upstream production, generated $18.9 billion in free cash flow, and returned $5.1 billion to sh...
Abraxas Capital is reported to have acquired about 13,000 ETH based on several large transfers from Binance to a wallet labeled as theirs on September 7, 2026. However, there is no confirmed evidence that these transfers represent a new purchase rath...
Aerodrome Finance surged 20.14% to $0.6569, leading crypto gainers due to growing interest in its decentralized finance ecosystem. Meanwhile, Arbitrum, a major Ethereum layer-2 project, fell 11.09% amid challenges sustaining recent gains. Other notab...
Worldcoin (WLD) surged over 13% in 24 hours, doubling weekly gains to 26%, driven by renewed AI interest and strong buying that triggered short liquidations exceeding $1.2 million. The altcoin broke above a key resistance zone ($0.41-$0.45), suggesti...
Prediction market bettors expect Bitcoin's price to remain volatile but largely stable around $80,000 by the end of 2026. Polymarket shows a 73% chance of Bitcoin reaching $85,000, while Kalshi's $35 million market centers predictions near $81,000. H...
